| __timestamp | Neurocrine Biosciences, Inc. | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 1802274 |
| Thursday, January 1, 2015 | 32480000 | 2512761 |
| Friday, January 1, 2016 | 68081000 | 2894488 |
| Sunday, January 1, 2017 | 169906000 | 8096274 |
| Monday, January 1, 2018 | 248932000 | 7985229 |
| Tuesday, January 1, 2019 | 354100000 | 8994597 |
| Wednesday, January 1, 2020 | 433300000 | 29772000 |
| Friday, January 1, 2021 | 583300000 | 33907000 |
| Saturday, January 1, 2022 | 752700000 | 26579000 |
| Sunday, January 1, 2023 | 887600000 | 49868547 |
| Monday, January 1, 2024 | 1007200000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing expenses is crucial for success. Neurocrine Biosciences, Inc. and Verona Pharma plc, two prominent players, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Neurocrine Biosciences has seen a staggering increase of nearly 4,800% in SG&A expenses, reflecting its aggressive growth and expansion strategies. In contrast, Verona Pharma's expenses have grown by approximately 2,700%, indicating a more measured approach.
By 2023, Neurocrine's SG&A expenses reached nearly $888 million, dwarfing Verona's $49 million. This disparity highlights the different scales and strategies of these companies. Neurocrine's rapid increase suggests significant investment in marketing and administrative capabilities, while Verona's steady rise may indicate a focus on sustainable growth. Understanding these trends provides valuable insights into the strategic priorities of these biotech firms.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Eli Lilly and Company vs Verona Pharma plc
Who Optimizes SG&A Costs Better? AbbVie Inc. or Verona Pharma plc
SG&A Efficiency Analysis: Comparing Novartis AG and Verona Pharma plc
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Verona Pharma plc and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights